Axsome Therapeutics Inc (NASDAQ:AXSM) price on Thursday, January 16, fall -0.06% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $93.69.
A look at the stock’s price movement, the close in the last trading session was $93.75, moving within a range at $92.7756 and $95.3563. The beta value (5-Year monthly) was 1.252. Turning to its 52-week performance, $105.00 and $64.11 were the 52-week high and 52-week low respectively. Overall, AXSM moved 3.98% over the past month.
Axsome Therapeutics Inc’s market cap currently stands at around $4.54 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 117.63M for the company’s revenue for the quarter, with a low and high estimate of 108.5M and 126.1M respectively. The average forecast suggests up to a 64.45% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 384.28M, representing a 42.01% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AXSM is a Hold. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
15 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 13 recommend AXSM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AXSM’s current price about 7.12% and 1.48% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.59, while 7-day volatility ratio is 6.96% and 5.30% in the 30-day chart. Further, Axsome Therapeutics Inc (AXSM) has a beta value of 1.03, and an average true range (ATR) of 4.71. Analysts have given the company’s stock an average 52-week price target of $133, forecast between a low of $106 and high of $180. Looking at the price targets, the low is -13.14% off current price level while to achieve the yearly target high, price needs to move -92.12%. Nonetheless, investors will most likely welcome a -41.96% jump to $133 which is the analysts’ median price.
If we refocus on Axsome Therapeutics Inc (NASDAQ:AXSM), historical trading data shows that trading volumes averaged 1.02 over the past 10 days and 644.29K over the past 3 months. The company’s latest data on shares outstanding shows there are 48.44 million shares.
The 18.28% of Axsome Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 79.22% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.62 million on 2024-12-31, giving us a short ratio of 9.72. The data shows that as of 2024-12-31 short interest in Axsome Therapeutics Inc (AXSM) stood at 1636.0001 of shares outstanding, with shares short falling to 7.08 million registered in 2024-11-29. Current price change has pushed the stock 10.73% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AXSM stock continues to rise going into the next quarter.
